June 9, 2022

XLock Biosciences’ CEO Dr. William Clarke has been awarded an SBIR Phase I grant from the NIH National Heart, Lung, and Blood Institute in the amount of $259,613 for his project titled “Development of an engineered CCL20 as a therapeutic molecule for chronic graft-versus-host disease”.